Skip to main content

Table 3 Preventive efficacy of various orally administered macrocyclic lactones against the macrocyclic lactone-resistant heartworm strain ZoeLA

From: Moxidectin: heartworm disease prevention in dogs in the face of emerging macrocyclic lactone resistance

Study

Treatment

Dosage (µg/kg)

Day of inoculationa

Days of treatment

Preventive efficacy (%)

References

1

Placebo

0

−30

0, 30, 60, 90, 120, 150

–

[50]

Simparica Trio (moxidectin)

Min. 24

−30

0, 30, 60, 90, 120, 150

97.2

[50]

Heartgard Plus (ivermectin)

Min. 6

−30

0, 30, 60, 90, 120, 150

8.5

[50]

Interceptor Plus (milbemycin oxime)

Min. 500

−30

0, 30, 60, 90, 120, 150

35.9

[50]

2

Placebo

0

−30

0, 30, 60, 90, 120, 150

–

[49]

Moxidectin

24

−30

0, 30, 60, 90

96.8

[49]

Moxidectin

24

−30

0, 30, 60, 90, 120, 150

96.1

[49]

Heartgard Plus (ivermectin)

Min. 6

−30

0, 30, 60, 90, 120, 150

18.7

[49]

Interceptor Plus (milbemycin oxime)

Min. 500

−30

0, 30, 60, 90, 120, 150

21.2

[49]

  1. aEach dog inoculated with 50 third-stage larvae (L3) of the ZoeLA, macrocyclic lactone-resistant strain